aberrations. Lastly, we were able to obtain drug response results within three weeks of :@0.147059:0.121273:0.886395:0.121273:0.886395:0.100900:0.147059:0.100900:0.009108:0.011254:0.009039:0.007807:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.005752:0.011984:0.009291:0.007510:0.006620:0.005182:0.007989:0.004497:0.005752:0.014518:0.009039:0.005752:0.014518:0.009039:0.007442:0.009039:0.005752:0.009108:0.010911:0.005182:0.009039:0.005752:0.006209:0.011048:0.005752:0.010957:0.010797:0.006551:0.009085:0.005615:0.011756:0.005752:0.011391:0.007967:0.011413:0.009861:0.005752:0.007442:0.009039:0.007512:0.011502:0.010843:0.011619:0.007875:0.009039:0.005752:0.007442:0.009039:0.007510:0.011550:0.004908:0.006437:0.007670:0.005752:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.005752:0.006620:0.011459:0.007442:0.009108:0.009039:0.005752:0.014518:0.009108:0.008948:0.010523:0.007670:0.005752:0.010843:0.006209:0.004109
tumor sampling, illustrating the short turnaround time needed for these assays, a critical :@0.147059:0.141852:0.886505:0.141852:0.886505:0.121479:0.147059:0.121479:0.006163:0.011413:0.017485:0.010843:0.007807:0.003903:0.007944:0.009085:0.017280:0.011162:0.005250:0.005615:0.011459:0.009679:0.004497:0.003903:0.005752:0.005387:0.004908:0.011413:0.007510:0.006437:0.007898:0.008811:0.006437:0.005615:0.011459:0.009861:0.003903:0.006620:0.011299:0.009039:0.003903:0.007556:0.011299:0.010843:0.007967:0.006437:0.003903:0.006163:0.011413:0.007807:0.011687:0.009085:0.007442:0.010820:0.011413:0.011596:0.011391:0.003903:0.006437:0.005615:0.017485:0.009039:0.003903:0.011596:0.009108:0.009106:0.011322:0.009108:0.011391:0.003903:0.006024:0.010845:0.007807:0.003903:0.006620:0.011299:0.009039:0.007875:0.009039:0.003903:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004497:0.003903:0.009291:0.003903:0.008994:0.007807:0.005273:0.006437:0.005545:0.009108:0.009405:0.005250:0.004109
feature for clinical implementation. Overall, these results highlighted the importance of :@0.147059:0.162431:0.886366:0.162431:0.886366:0.142058:0.147059:0.142058:0.006026:0.009291:0.008811:0.006163:0.011413:0.007442:0.009039:0.004520:0.006026:0.010843:0.007807:0.004520:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004520:0.005615:0.017278:0.011162:0.005182:0.009039:0.017488:0.009039:0.011391:0.006549:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.004520:0.016890:0.009635:0.009039:0.007896:0.009405:0.005387:0.004976:0.004497:0.004520:0.006620:0.011299:0.009039:0.007875:0.009039:0.004520:0.007442:0.009039:0.007510:0.011550:0.004908:0.006437:0.007670:0.004520:0.011459:0.005615:0.009930:0.011573:0.005250:0.005615:0.009927:0.011096:0.006209:0.009106:0.011391:0.004520:0.006617:0.011302:0.009039:0.004520:0.005615:0.017280:0.011505:0.010843:0.007967:0.006551:0.009085:0.011596:0.008994:0.009039:0.004520:0.010843:0.006209:0.004109
deriving PDO lines from multiple tumor locations of a patient, when applicable, to im-:@0.147059:0.183009:0.882353:0.183009:0.882353:0.162636:0.147059:0.162636:0.011322:0.009039:0.007807:0.005547:0.009838:0.005615:0.011459:0.009861:0.004885:0.011664:0.016504:0.016412:0.004885:0.005250:0.005615:0.011596:0.009039:0.007670:0.004885:0.006414:0.007442:0.010843:0.017645:0.004885:0.017280:0.011550:0.004908:0.006437:0.005271:0.011162:0.005182:0.009039:0.004885:0.006163:0.011413:0.017485:0.010843:0.007807:0.004885:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004885:0.010843:0.006209:0.004885:0.009291:0.004885:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004497:0.004885:0.014792:0.011299:0.009039:0.011756:0.004885:0.008811:0.011048:0.011162:0.005250:0.005545:0.009108:0.009110:0.010909:0.005182:0.008743:0.004497:0.004885:0.006209:0.011048:0.004885:0.005615:0.017647:0.007533
prove drug response prediction and clinical decision making based on PDO assays. :@0.147059:0.203588:0.847880:0.203588:0.847880:0.183215:0.147059:0.183215:0.011071:0.007442:0.010866:0.009633:0.009039:0.004109:0.011391:0.007967:0.011413:0.009861:0.004109:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007873:0.009039:0.004109:0.011071:0.007442:0.009108:0.011391:0.005547:0.009108:0.006437:0.005547:0.010843:0.011756:0.004109:0.009085:0.011596:0.011391:0.004109:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004109:0.011322:0.009106:0.008994:0.005615:0.007601:0.005547:0.010843:0.011756:0.004109:0.017577:0.009405:0.010706:0.005615:0.011459:0.009861:0.004109:0.011117:0.009291:0.007875:0.009106:0.011391:0.004109:0.010843:0.011756:0.004109:0.011664:0.016504:0.016412:0.004109:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004497:0.004109
In the second part of the thesis I focused on somatic structural variation in cancer. Ac-:@0.147059:0.244745:0.882353:0.244745:0.882353:0.224373:0.147059:0.224373:0.006894:0.011756:0.005045:0.006620:0.011299:0.009039:0.005045:0.007875:0.009108:0.008994:0.010843:0.011596:0.011391:0.005045:0.011368:0.009085:0.007967:0.006437:0.005045:0.010843:0.006209:0.005045:0.006620:0.011299:0.009039:0.005045:0.006620:0.011299:0.009039:0.007601:0.005615:0.007670:0.005045:0.007259:0.005045:0.006026:0.011276:0.009108:0.011413:0.007873:0.009108:0.011391:0.005045:0.010843:0.011756:0.005045:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.005045:0.007510:0.006437:0.007967:0.011345:0.009108:0.006163:0.011413:0.007898:0.009405:0.005250:0.005045:0.009838:0.009085:0.007807:0.005798:0.008811:0.006437:0.005547:0.010843:0.011756:0.005045:0.005615:0.011756:0.005045:0.009108:0.009085:0.011596:0.008994:0.009039:0.006255:0.004497:0.005045:0.014335:0.009131:0.007533
curate detection of structural variants (SVs) is still challenging, and truth sets and stan-:@0.147059:0.265324:0.882353:0.265324:0.882353:0.244951:0.147059:0.244951:0.009108:0.011413:0.007898:0.008811:0.006209:0.009039:0.004871:0.011322:0.009131:0.006211:0.009106:0.009108:0.006437:0.005547:0.010843:0.011756:0.004874:0.010843:0.006209:0.004874:0.007510:0.006437:0.007964:0.011347:0.009106:0.006166:0.011413:0.007898:0.009402:0.005250:0.004874:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.004874:0.006939:0.010112:0.015089:0.007670:0.006939:0.004871:0.005615:0.007670:0.004871:0.007512:0.006437:0.005750:0.005387:0.005250:0.004874:0.008765:0.011391:0.009405:0.005387:0.005182:0.009039:0.011459:0.009861:0.005615:0.011459:0.009679:0.004497:0.004874:0.009085:0.011596:0.011391:0.004871:0.006437:0.007967:0.011071:0.006620:0.011459:0.004874:0.007875:0.009131:0.006437:0.007670:0.004871:0.009087:0.011596:0.011391:0.004871:0.007510:0.006551:0.009085:0.011756:0.007533
dardized workflows are lacking. We tackled the challenge of accurate somatic SV detec-:@0.147059:0.285903:0.882353:0.285903:0.882353:0.265530:0.147059:0.265530:0.011573:0.009085:0.007442:0.011391:0.005615:0.008834:0.009108:0.011391:0.004588:0.014518:0.010843:0.007601:0.010706:0.005638:0.005570:0.010866:0.014723:0.007670:0.004588:0.009085:0.007442:0.009039:0.004588:0.005433:0.009291:0.008765:0.010706:0.005615:0.011459:0.009679:0.004497:0.004588:0.018649:0.009039:0.004588:0.006551:0.009291:0.008765:0.010886:0.005182:0.009108:0.011391:0.004588:0.006620:0.011302:0.009039:0.004588:0.008765:0.011391:0.009405:0.005387:0.005182:0.009039:0.011459:0.009656:0.009039:0.004588:0.010843:0.006209:0.004588:0.009291:0.008994:0.009108:0.011413:0.007898:0.008811:0.006209:0.009039:0.004588:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004588:0.010112:0.015089:0.004588:0.011322:0.009131:0.006209:0.009106:0.009108:0.007533
tion in cancer genomes and generated a truth set of somatic SVs that can be used for :@0.147059:0.306482:0.886459:0.306482:0.886459:0.286109:0.147059:0.286109:0.006437:0.005547:0.010843:0.011756:0.006081:0.005615:0.011756:0.006081:0.009108:0.009085:0.011598:0.008994:0.009039:0.007807:0.006081:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.007670:0.006081:0.009085:0.011598:0.011391:0.006081:0.009656:0.009039:0.011596:0.009039:0.007898:0.008811:0.006209:0.009108:0.011391:0.006081:0.009291:0.006081:0.006437:0.007967:0.011071:0.006620:0.011459:0.006081:0.007875:0.009131:0.006437:0.006083:0.010843:0.006209:0.006081:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.006081:0.010112:0.015089:0.007670:0.006081:0.006620:0.011391:0.008811:0.006437:0.006083:0.009108:0.009085:0.011756:0.006081:0.011254:0.009039:0.006081:0.011413:0.007875:0.009108:0.011391:0.006081:0.006026:0.010843:0.007807:0.004109
method development and benchmarking, which I presented in :@0.147059:0.327060:0.672143:0.327060:0.672143:0.306687:0.147059:0.306687:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.003356:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011071:0.017485:0.009039:0.011391:0.006437:0.003356:0.009087:0.011596:0.011391:0.003356:0.011254:0.009039:0.011596:0.008765:0.011459:0.017577:0.009085:0.007601:0.010706:0.005615:0.011459:0.009679:0.004497:0.003356:0.014792:0.011459:0.005547:0.008765:0.011459:0.003356:0.007259:0.003356:0.011071:0.007442:0.009039:0.007873:0.009039:0.011391:0.006211:0.009106:0.011391:0.003356:0.005615:0.011756:0.004109
chapter 4:@0.671393:0.327060:0.752451:0.327060:0.752451:0.305927:0.671393:0.305927:0.009085:0.011779:0.009542:0.011733:0.006871:0.009268:0.008583:0.003287:0.010911
. We performed :@0.752445:0.327060:0.886459:0.327060:0.886459:0.306687:0.752445:0.306687:0.004497:0.003356:0.018649:0.009039:0.003356:0.011502:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.004109
genome-wide analysis of the paired melanoma and normal lymphoblastoid COLO829 :@0.147059:0.347639:0.886418:0.347639:0.886418:0.327266:0.147059:0.327266:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.007533:0.014723:0.005547:0.011322:0.009039:0.005319:0.009085:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.005319:0.010843:0.006209:0.005319:0.006620:0.011299:0.009039:0.005319:0.011368:0.009085:0.005615:0.007442:0.009108:0.011391:0.005319:0.017485:0.008948:0.005433:0.009085:0.011596:0.010843:0.017577:0.009291:0.005319:0.009085:0.011596:0.011391:0.005319:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.005319:0.005182:0.009724:0.017280:0.011162:0.011299:0.010957:0.010911:0.005433:0.009291:0.007510:0.006209:0.010843:0.005547:0.011391:0.005319:0.014746:0.016047:0.011528:0.016412:0.010432:0.010432:0.010432:0.004109
cell lines. We sequenced these cell lines to a high depth using four different sequencing :@0.147059:0.368218:0.886507:0.368218:0.886507:0.347845:0.147059:0.347845:0.008994:0.008948:0.005387:0.005250:0.005022:0.005250:0.005615:0.011596:0.009039:0.007670:0.004497:0.005022:0.018649:0.009039:0.005022:0.007875:0.009108:0.010703:0.011347:0.009039:0.011596:0.008994:0.009106:0.011391:0.005022:0.006620:0.011299:0.009039:0.007875:0.009039:0.005022:0.008994:0.008948:0.005387:0.005250:0.005022:0.005250:0.005615:0.011596:0.009039:0.007670:0.005022:0.006209:0.011048:0.005022:0.009291:0.005022:0.011459:0.005615:0.009930:0.011459:0.005022:0.011322:0.009131:0.011048:0.006620:0.011459:0.005022:0.011413:0.007601:0.005615:0.011459:0.009861:0.005022:0.006026:0.010820:0.011413:0.007807:0.005022:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005022:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004109
technologies: Illumina, Oxford Nanopore, Pacific Biosciences and 10X Genomics. We :@0.147059:0.388796:0.886462:0.388796:0.886462:0.368423:0.147059:0.368423:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005547:0.009039:0.007670:0.004497:0.006095:0.007190:0.005387:0.004908:0.011413:0.017645:0.005615:0.011687:0.009291:0.004497:0.006095:0.016298:0.010089:0.006024:0.010843:0.007442:0.011391:0.006095:0.015545:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.008743:0.004497:0.006095:0.011413:0.009291:0.008994:0.005615:0.005684:0.005615:0.008994:0.006095:0.012486:0.005547:0.010957:0.007875:0.008994:0.005547:0.009039:0.011596:0.008994:0.009039:0.007670:0.006095:0.009085:0.011596:0.011391:0.006095:0.010432:0.010432:0.014107:0.006095:0.015819:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.007670:0.004497:0.006095:0.018649:0.009039:0.004109
also performed experimental validation, including Bionano optical mapping data, to en-:@0.147059:0.409375:0.882353:0.409375:0.882353:0.389002:0.147059:0.389002:0.009405:0.005250:0.007875:0.011048:0.003675:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017483:0.009108:0.011391:0.003675:0.009108:0.010089:0.011505:0.009039:0.007807:0.005615:0.017485:0.009039:0.011391:0.006551:0.009405:0.005250:0.003675:0.009838:0.009405:0.005250:0.005547:0.011571:0.008813:0.006437:0.005545:0.010845:0.011756:0.004497:0.003675:0.005615:0.011596:0.008763:0.004910:0.011345:0.011391:0.005615:0.011459:0.009861:0.003675:0.012486:0.005547:0.010843:0.011687:0.009085:0.011596:0.011048:0.003675:0.010820:0.011048:0.006437:0.005547:0.009108:0.009402:0.005250:0.003675:0.017577:0.008811:0.011048:0.011071:0.005615:0.011459:0.009861:0.003675:0.011573:0.008811:0.006551:0.009291:0.004497:0.003675:0.006209:0.011048:0.003675:0.009039:0.011712:0.007533
sure that the truth set was reliable and complete. Finally, we demonstrated the utility of :@0.147059:0.429954:0.886464:0.429954:0.886464:0.409581:0.147059:0.409581:0.007510:0.011413:0.007442:0.009039:0.004919:0.006620:0.011391:0.008811:0.006437:0.004919:0.006620:0.011299:0.009039:0.004919:0.006437:0.007967:0.011071:0.006620:0.011459:0.004919:0.007875:0.009131:0.006437:0.004919:0.014723:0.009291:0.007670:0.004919:0.007442:0.008948:0.005250:0.005798:0.009108:0.010911:0.005182:0.009039:0.004919:0.009085:0.011596:0.011391:0.004919:0.008994:0.010843:0.017280:0.011162:0.005182:0.009131:0.006209:0.008743:0.004497:0.004919:0.011391:0.005615:0.011687:0.009405:0.005387:0.005182:0.007989:0.004497:0.004919:0.014518:0.009039:0.004919:0.011322:0.009039:0.017485:0.010843:0.011619:0.007510:0.006437:0.007898:0.008811:0.006209:0.009108:0.011391:0.004919:0.006620:0.011299:0.009039:0.004919:0.011071:0.006437:0.005752:0.005250:0.005273:0.006437:0.009724:0.004919:0.010843:0.006209:0.004109
the truth set by determining the SV detection performance of each technology as a func-:@0.147059:0.450532:0.882353:0.450532:0.882353:0.430160:0.147059:0.430160:0.006620:0.011299:0.009039:0.003698:0.006437:0.007967:0.011071:0.006620:0.011459:0.003698:0.007875:0.009131:0.006437:0.003698:0.010843:0.009724:0.003698:0.011322:0.009131:0.006209:0.009039:0.007807:0.017645:0.005615:0.011756:0.005615:0.011457:0.009861:0.003698:0.006620:0.011299:0.009039:0.003698:0.010112:0.015089:0.003698:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.003698:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017577:0.009085:0.011596:0.008994:0.009039:0.003698:0.010843:0.006209:0.003698:0.009291:0.009291:0.008765:0.011459:0.003698:0.006209:0.009106:0.008765:0.011459:0.011598:0.010932:0.005184:0.011048:0.010544:0.009724:0.003698:0.009291:0.007670:0.003698:0.009291:0.003698:0.006369:0.011413:0.011596:0.009019:0.007533
tion of tumor purity and sequencing depth. This gold-standard truth set, together with :@0.147059:0.471111:0.886551:0.471111:0.886551:0.450738:0.147059:0.450738:0.006437:0.005547:0.010843:0.011756:0.005090:0.010843:0.006209:0.005090:0.006163:0.011413:0.017485:0.010843:0.007807:0.005090:0.011048:0.011413:0.007807:0.005273:0.006437:0.009724:0.005079:0.009085:0.011598:0.011391:0.005079:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005090:0.011322:0.009131:0.011048:0.006620:0.011459:0.004497:0.005090:0.011470:0.011470:0.005615:0.007670:0.005079:0.009656:0.010934:0.005182:0.011391:0.007533:0.007510:0.006551:0.009085:0.011596:0.011573:0.009085:0.007442:0.011391:0.005090:0.006437:0.007967:0.011071:0.006620:0.011459:0.005090:0.007875:0.009131:0.006437:0.004497:0.005090:0.006211:0.011048:0.009658:0.009128:0.006620:0.011302:0.009039:0.007807:0.005090:0.014723:0.005273:0.006620:0.011459:0.004109
the underlying multi-platform genomic characterization of this cancer cell line pair, are :@0.147059:0.491690:0.886416:0.491690:0.886416:0.471317:0.147059:0.471317:0.006620:0.011299:0.009039:0.004702:0.011413:0.011596:0.011322:0.009039:0.007601:0.005182:0.009724:0.005615:0.011459:0.009861:0.004702:0.017280:0.011550:0.004908:0.006437:0.005615:0.007533:0.011160:0.005433:0.008811:0.006437:0.006026:0.010843:0.007807:0.017645:0.004702:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004702:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.008811:0.006437:0.005547:0.010843:0.011756:0.004702:0.010843:0.006209:0.004702:0.006620:0.011459:0.005615:0.007670:0.004702:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004702:0.008994:0.008948:0.005387:0.005250:0.004702:0.005250:0.005615:0.011596:0.009039:0.004702:0.011368:0.009085:0.005615:0.006255:0.004497:0.004702:0.009085:0.007442:0.009039:0.004109
an important resource for benchmarking and method development efforts in the cancer :@0.147059:0.512269:0.886487:0.512269:0.886487:0.491896:0.147059:0.491896:0.009085:0.011756:0.003949:0.005615:0.017280:0.011505:0.010843:0.007967:0.006551:0.009085:0.011391:0.006437:0.003949:0.007442:0.009039:0.007875:0.010820:0.011413:0.007442:0.008994:0.009039:0.003949:0.006026:0.010843:0.007807:0.003949:0.011254:0.009039:0.011596:0.008765:0.011459:0.017577:0.009085:0.007601:0.010706:0.005615:0.011459:0.009861:0.003949:0.009085:0.011596:0.011391:0.003949:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.003949:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011071:0.017485:0.009039:0.011391:0.006437:0.003949:0.009039:0.005969:0.005787:0.010843:0.007967:0.006437:0.007670:0.003949:0.005615:0.011756:0.003949:0.006620:0.011299:0.009039:0.003949:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004109
genomics community. :@0.147059:0.532847:0.338393:0.532847:0.338393:0.512474:0.147059:0.512474:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.007670:0.004109:0.008994:0.010843:0.017645:0.017280:0.011413:0.011756:0.005273:0.006437:0.007989:0.004497:0.004109
Furthermore, we developed methods to utilize long-read sequencing and somatic struc-:@0.147059:0.574005:0.882353:0.574005:0.882353:0.553632:0.147059:0.553632:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004063:0.014518:0.009039:0.004063:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011505:0.009108:0.011391:0.004063:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.007670:0.004063:0.006209:0.011048:0.004063:0.011071:0.006437:0.005752:0.005250:0.005615:0.008834:0.009039:0.004063:0.005182:0.010843:0.011459:0.009861:0.007533:0.007442:0.009291:0.009291:0.011391:0.004063:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004063:0.009085:0.011596:0.011391:0.004063:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004063:0.007510:0.006437:0.007967:0.011345:0.009014:0.007533
tural variants (SVs) for cancer dynamics after treatment and minimal residual disease :@0.147059:0.594583:0.886535:0.594583:0.886535:0.574210:0.147059:0.574210:0.006163:0.011413:0.007898:0.009405:0.005250:0.006026:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.006026:0.006939:0.010112:0.015089:0.007670:0.006939:0.006026:0.006026:0.010843:0.007807:0.006026:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.006026:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.007670:0.006026:0.009085:0.006197:0.005971:0.009039:0.007807:0.006026:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.006026:0.009085:0.011596:0.011391:0.006026:0.017645:0.005615:0.011756:0.005615:0.017577:0.009405:0.005250:0.006026:0.007442:0.009039:0.007601:0.005547:0.011048:0.011596:0.009405:0.005250:0.006026:0.011391:0.005615:0.007875:0.009291:0.009291:0.007875:0.009039:0.004109
tracing. In :@0.147059:0.615162:0.238777:0.615162:0.238777:0.594789:0.147059:0.594789:0.006437:0.007898:0.009291:0.008994:0.005615:0.011459:0.009679:0.004497:0.005090:0.006894:0.011756:0.004109
chapter 5:@0.239773:0.615162:0.322520:0.615162:0.322520:0.594029:0.239773:0.594029:0.009085:0.011779:0.009542:0.011733:0.006871:0.009268:0.008583:0.004976:0.010911
, we developed an assay that leveraged nanopore sequencing tech-:@0.322528:0.615162:0.882353:0.615162:0.882353:0.594789:0.322528:0.594789:0.004497:0.005090:0.014518:0.009039:0.005090:0.011322:0.009334:0.009633:0.008948:0.005182:0.010822:0.011502:0.009108:0.011391:0.005090:0.009085:0.011756:0.005090:0.009291:0.007533:0.007944:0.008925:0.009724:0.005090:0.006620:0.011391:0.008811:0.006437:0.005090:0.005182:0.009334:0.009633:0.009039:0.007898:0.009199:0.009656:0.009108:0.011391:0.005090:0.011687:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.005090:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005090:0.006209:0.009108:0.008765:0.011530:0.007533
nology for rapid detection of somatic SVs from a tumor. We used low-coverage whole-ge-:@0.147059:0.635741:0.882353:0.635741:0.882353:0.615368:0.147059:0.615368:0.011596:0.010934:0.005182:0.011048:0.010546:0.009724:0.002922:0.006026:0.010843:0.007807:0.002922:0.007896:0.008811:0.011073:0.005547:0.011391:0.002922:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.002922:0.010843:0.006209:0.002922:0.007875:0.010840:0.017579:0.008811:0.006437:0.005547:0.008994:0.002922:0.010112:0.015089:0.007670:0.002922:0.006414:0.007442:0.010843:0.017645:0.002922:0.009291:0.002922:0.006163:0.011413:0.017485:0.010843:0.006255:0.004497:0.002922:0.018647:0.009039:0.002922:0.011413:0.007875:0.009108:0.011391:0.002922:0.005182:0.010866:0.014723:0.007533:0.008994:0.010863:0.009635:0.009039:0.007896:0.009201:0.009656:0.009039:0.002922:0.014792:0.011299:0.010934:0.005182:0.009039:0.007533:0.009656:0.009062:0.007533
nome sequencing of a tumor with nanopore technology and then used filtering and :@0.147059:0.656319:0.886464:0.656319:0.886464:0.635947:0.147059:0.635947:0.011596:0.010843:0.017485:0.009039:0.007248:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.007248:0.010843:0.006209:0.007248:0.009291:0.007248:0.006163:0.011413:0.017485:0.010843:0.007807:0.007248:0.014723:0.005271:0.006620:0.011459:0.007248:0.011690:0.009085:0.011596:0.010820:0.011502:0.010845:0.007442:0.009039:0.007245:0.006211:0.009106:0.008768:0.011459:0.011596:0.010934:0.005182:0.011048:0.010544:0.009724:0.007248:0.009087:0.011596:0.011391:0.007245:0.006620:0.011302:0.009039:0.011756:0.007248:0.011413:0.007875:0.009108:0.011391:0.007248:0.005684:0.005821:0.004908:0.006209:0.009039:0.007807:0.005615:0.011459:0.009861:0.007248:0.009085:0.011596:0.011391:0.004109
random-forest classification to select the most likely somatic SV candidates. We could re-:@0.147059:0.676898:0.882353:0.676898:0.882353:0.656525:0.147059:0.656525:0.007898:0.009085:0.011596:0.011322:0.010843:0.017645:0.007533:0.006026:0.010843:0.007442:0.009039:0.007510:0.006437:0.003356:0.008765:0.005433:0.009291:0.007533:0.007601:0.005615:0.005684:0.005613:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.003356:0.006209:0.011048:0.003356:0.007875:0.008948:0.005182:0.009108:0.009108:0.006437:0.003356:0.006620:0.011299:0.009039:0.003356:0.017485:0.010957:0.007510:0.006437:0.003356:0.005250:0.005752:0.010272:0.008948:0.005182:0.009724:0.003356:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.003356:0.010112:0.015089:0.003356:0.009108:0.009085:0.011596:0.011391:0.005547:0.011573:0.008811:0.006209:0.009039:0.007670:0.004497:0.003356:0.018649:0.009039:0.003356:0.008994:0.010820:0.011550:0.005182:0.011391:0.003356:0.007442:0.008971:0.007533
trieve these biomarker-candidates within three days after tissue obtention. These somatic :@0.147059:0.697477:0.886398:0.697477:0.886398:0.677104:0.147059:0.677104:0.006437:0.007807:0.005547:0.009336:0.009633:0.009039:0.003310:0.006620:0.011299:0.009039:0.007875:0.009039:0.003310:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007236:0.007533:0.009108:0.009085:0.011596:0.011391:0.005547:0.011573:0.008811:0.006209:0.009039:0.007670:0.003310:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.003310:0.006620:0.011459:0.007442:0.009108:0.009039:0.003310:0.011573:0.008925:0.009724:0.007670:0.003310:0.009085:0.006197:0.005969:0.009039:0.007807:0.003310:0.006437:0.005615:0.007533:0.007510:0.011347:0.009039:0.003310:0.010957:0.010795:0.006209:0.009039:0.011391:0.006437:0.005547:0.010845:0.011756:0.004497:0.003310:0.011470:0.011311:0.009039:0.007875:0.009039:0.003310:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004109
SVs could be used, after validation, as patient-specific biomarkers for cancer tracking in :@0.147059:0.718056:0.886530:0.718056:0.886530:0.697683:0.147059:0.697683:0.010112:0.015089:0.007670:0.004360:0.008994:0.010820:0.011550:0.005182:0.011391:0.004360:0.011254:0.009039:0.004360:0.011413:0.007875:0.009108:0.011117:0.004497:0.004360:0.009087:0.006197:0.005969:0.009039:0.007807:0.004360:0.009838:0.009405:0.005250:0.005547:0.011573:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.004360:0.009291:0.007670:0.004360:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011502:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004360:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.004360:0.006024:0.010843:0.007807:0.004360:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004360:0.006437:0.007898:0.009291:0.008765:0.010706:0.005615:0.011459:0.009861:0.004360:0.005615:0.011756:0.004109
circulating tumor DNA (ctDNA) by ultra-sensitive PCR methods. We applied our assay :@0.147059:0.738634:0.886462:0.738634:0.886462:0.718261:0.147059:0.718261:0.008994:0.005615:0.007442:0.009108:0.011550:0.005433:0.008811:0.006437:0.005615:0.011459:0.009861:0.004209:0.006163:0.011413:0.017485:0.010843:0.007807:0.004212:0.015773:0.015408:0.014929:0.004209:0.006939:0.009108:0.006437:0.015773:0.015408:0.014929:0.006939:0.004212:0.010840:0.009724:0.004212:0.011550:0.004908:0.006437:0.007898:0.009291:0.007533:0.007875:0.009039:0.011619:0.007601:0.005271:0.006437:0.005549:0.009633:0.009039:0.004209:0.012167:0.014678:0.013376:0.004212:0.017485:0.009131:0.006617:0.011302:0.011274:0.011391:0.007670:0.004497:0.004212:0.018649:0.009039:0.004209:0.008813:0.011048:0.011162:0.005250:0.005547:0.009108:0.011391:0.004212:0.010820:0.011413:0.007807:0.004209:0.009291:0.007533:0.007944:0.008925:0.009724:0.004109
to ten ovarian and prostate cancer samples and obtained multiple biomarkers per sample :@0.147059:0.759213:0.886350:0.759213:0.886350:0.738840:0.147059:0.738840:0.006209:0.011048:0.003492:0.006209:0.009039:0.011756:0.003492:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.003492:0.009085:0.011596:0.011391:0.003492:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.003492:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.003492:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.003492:0.009085:0.011596:0.011391:0.003492:0.010957:0.010797:0.006551:0.009085:0.005615:0.011596:0.009108:0.011391:0.003492:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.003492:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.003492:0.011505:0.009039:0.007807:0.003492:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.004109
in mere days. We demonstrated retrospectively that longitudinal monitoring of cancer :@0.147059:0.779792:0.886478:0.779792:0.886478:0.759419:0.147059:0.759419:0.005615:0.011756:0.005650:0.017485:0.009039:0.007442:0.009039:0.005650:0.011573:0.008925:0.009724:0.007670:0.004497:0.005650:0.018649:0.009039:0.005650:0.011322:0.009039:0.017485:0.010843:0.011619:0.007510:0.006437:0.007898:0.008811:0.006209:0.009108:0.011391:0.005650:0.007442:0.009131:0.006437:0.007442:0.010957:0.007510:0.011505:0.009108:0.009106:0.006437:0.005547:0.009635:0.008948:0.005182:0.009724:0.005650:0.006620:0.011391:0.008811:0.006437:0.005650:0.005182:0.010843:0.011459:0.009861:0.005273:0.006163:0.011345:0.011391:0.005615:0.011687:0.009405:0.005250:0.005661:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011461:0.009861:0.005650:0.010843:0.006209:0.005650:0.009106:0.009087:0.011596:0.008994:0.009039:0.007807:0.004109
dynamics was feasible using these somatic SV biomarkers. Summarizing, our method :@0.147059:0.800370:0.886535:0.800370:0.886535:0.779998:0.147059:0.779998:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.007670:0.006118:0.014723:0.009291:0.007670:0.006118:0.006026:0.009291:0.009291:0.007601:0.005547:0.010911:0.005182:0.009039:0.006118:0.011413:0.007601:0.005615:0.011459:0.009861:0.006118:0.006620:0.011299:0.009039:0.007875:0.009039:0.006118:0.007873:0.010843:0.017579:0.008809:0.006437:0.005547:0.008994:0.006118:0.010112:0.015089:0.006118:0.010820:0.005547:0.010843:0.017577:0.009085:0.007604:0.010272:0.009039:0.007624:0.007670:0.004497:0.006118:0.009795:0.011413:0.017645:0.017577:0.009085:0.007807:0.005615:0.008834:0.005615:0.011459:0.009679:0.004497:0.006118:0.010820:0.011413:0.007807:0.006118:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.004109
enabled rapid and cost-effective identification of a set of patient-specific SVs that can be :@0.147059:0.820949:0.886462:0.820949:0.886462:0.800576:0.147059:0.800576:0.009039:0.011687:0.009108:0.010911:0.005182:0.009108:0.011391:0.004234:0.007898:0.008809:0.011073:0.005547:0.011391:0.004232:0.009085:0.011598:0.011391:0.004232:0.008994:0.010957:0.007510:0.006437:0.007533:0.009039:0.005969:0.005787:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.004232:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004234:0.010843:0.006209:0.004234:0.009291:0.004232:0.007875:0.009131:0.006437:0.004234:0.010843:0.006209:0.004232:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004232:0.010112:0.015089:0.007670:0.004234:0.006620:0.011391:0.008811:0.006437:0.004234:0.009108:0.009085:0.011756:0.004232:0.011254:0.009039:0.004109
used to study ctDNA dynamics. :@0.147059:0.841528:0.418535:0.841528:0.418535:0.821155:0.147059:0.821155:0.011413:0.007875:0.009108:0.011391:0.004109:0.006209:0.011048:0.004109:0.007510:0.006163:0.011345:0.011322:0.009724:0.004109:0.009108:0.006437:0.015771:0.015408:0.014929:0.004109:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.007670:0.004497:0.004109
We also developed an assay that leverages CRISPR-Cas9 based enrichment of genom-:@0.147059:0.882685:0.882353:0.882685:0.882353:0.862312:0.147059:0.862312:0.018649:0.009039:0.005707:0.009405:0.005250:0.007875:0.011048:0.005707:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011505:0.009108:0.011391:0.005707:0.009085:0.011756:0.005707:0.009291:0.007533:0.007944:0.008925:0.009724:0.005707:0.006620:0.011391:0.008811:0.006437:0.005707:0.005182:0.009336:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.007670:0.005707:0.014678:0.013376:0.007259:0.009770:0.011664:0.012349:0.007533:0.014972:0.009291:0.007670:0.010432:0.005707:0.011117:0.009291:0.007875:0.009108:0.011391:0.005707:0.009039:0.011756:0.007807:0.005547:0.008765:0.011459:0.017485:0.009039:0.011391:0.006437:0.005707:0.010843:0.006209:0.005707:0.009656:0.009039:0.011596:0.010843:0.017622:0.007533
ic targets in pediatric leukemias from the lymphoid lineage. In :@0.147059:0.903264:0.688143:0.903264:0.688143:0.882891:0.147059:0.882891:0.005547:0.008994:0.005967:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.005969:0.005615:0.011756:0.005967:0.011505:0.009108:0.011391:0.005798:0.008811:0.006437:0.007807:0.005547:0.008994:0.005967:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.007670:0.005967:0.006414:0.007442:0.010843:0.017645:0.005969:0.006620:0.011299:0.009039:0.005967:0.005182:0.009724:0.017280:0.011162:0.011299:0.010843:0.005547:0.011391:0.005969:0.005250:0.005615:0.011596:0.009291:0.009199:0.009656:0.008743:0.004497:0.005967:0.006894:0.011756:0.004109
chapter 6:@0.690003:0.903264:0.773617:0.903264:0.773617:0.882131:0.690003:0.882131:0.009085:0.011779:0.009542:0.011733:0.006871:0.009268:0.008583:0.005844:0.010911
, we targeted :@0.773609:0.903264:0.886464:0.903264:0.886464:0.882891:0.773609:0.882891:0.004497:0.005969:0.014518:0.009042:0.005967:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004109
209:@0.890196:0.957873:0.915969:0.957873:0.915969:0.938882:0.890196:0.938882:0.008591:0.008591:0.008591
SUMMARY:@0.806592:0.066557:0.882582:0.066557:0.882582:0.045634:0.806592:0.045634:0.009542:0.010226:0.013582:0.013582:0.009679:0.009930:0.009450